Imatinib Mesylate c-Kit Receptor Blockade Addiction Relapse
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for addiction, particularly nicotine addiction and opioid analgesic-induced addiction, face challenges with high relapse rates and adverse side effects, lacking effective and sustainable solutions.
Innovation Solution
The use of imatinib mesylate, either alone or in combination with addictive substances, to create compound preparations that target the c-kit receptor, inhibiting addiction pathways and reducing withdrawal symptoms and relapse, with specific dose ratios and administration methods.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional addiction treatments (bupropion, clonidine, nortriptyline) are used, then nicotine dependence is reduced to some extent, but side effects increase and sustainable effect decreases
Solution Approach 1:
The patent changes the pharmacological target parameter from traditional nicotine replacement therapies to c-Kit receptor inhibition using imatinib. This parameter change in the mechanism of action achieves both reduction of nicotine dependence and prevention of relapse without the severe side effects associated with conventional treatments like bupropion, clonidine, and nortriptyline.
Solution Approach 2:
The patent extracts and addresses the root cause of relapse by specifically targeting the c-Kit receptor pathway that is activated during withdrawal and craving. By isolating and blocking this specific molecular mechanism with imatinib, the treatment prevents relapse without affecting the sustainable reduction of nicotine dependence achieved by conventional therapies.
2Reliability
If imatinib is used at higher doses to prevent relapse, then relapse prevention improves, but potential side effects may increase
Solution Approach 1:
The patent applies partial action by using a specific dose range of imatinib (5-400 mg/day) that is sufficient to block the c-Kit receptor pathway and prevent relapse, but not excessive enough to cause significant side effects. This optimized dosing strategy achieves effective relapse prevention while maintaining an acceptable safety profile.
3Reliability
If lifelong replacement therapy is used, then addiction symptoms are managed, but treatment complexity and duration increase
Solution Approach 1:
The patent applies preliminary action by using imatinib during the critical withdrawal and craving phase to prevent the formation of strong relapse tendencies. By intervening early in the addiction recovery process and blocking the c-Kit pathway before relapse can occur, the treatment reduces the need for lifelong replacement therapy and simplifies the overall treatment system.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Imatinib mesylate effectively prevents and treats addiction by blocking key signaling molecules, reducing relapse rates and alleviating withdrawal symptoms, while minimizing side effects, thus offering a more sustainable treatment option.
Implementation Method 1
Imatinib mesylate, either alone or in combination with addictive substances, to create compound preparations that target the c-kit receptor, inhibiting addiction pathways
Data Source
AI summary
A method for prevention and treatment of addictions and control of relapse comprising administering a patient in need thereof a composition comprising imatinib or a derivative thereof, and an addictive substance or an analgesic agent; wherein the addictive substance comprises: (1) narcotic drugs, (2) psychotropic drugs, (3) ethanol, tobacco, volatile organic solvents, and other substances leading to addictions in organisms, and analogues thereof; and (4) nicotine or an analogue thereof.